Clinical Trials Logo

Central Precocious Puberty clinical trials

View clinical trials related to Central Precocious Puberty.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06129539 Recruiting - Clinical trials for Central Precocious Puberty

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty

LIBELULA
Start date: July 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants receiving gonadotropin-releasing hormone agonist (GnRHa) therapy for central precocious puberty (CPP).

NCT ID: NCT06025409 Recruiting - Clinical trials for Central Precocious Puberty

Evaluate the Efficacy and Safety of DWJ108J

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.

NCT ID: NCT05341115 Recruiting - Clinical trials for Central Precocious Puberty

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Start date: March 14, 2023
Phase: Phase 4
Study type: Interventional

The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.

NCT ID: NCT02811471 Recruiting - Clinical trials for Central Precocious Puberty

Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Start date: June 2016
Phase: Phase 3
Study type: Interventional

Exploring the efficacy in Leuprolide 45mg in slowing down or reversing Central Precocious Puberty in girls ages 2-8 and boys ages 2-9.

NCT ID: NCT00438217 Recruiting - Clinical trials for Central Precocious Puberty

Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children

CPP-EDG 01
Start date: n/a
Phase: Phase 4
Study type: Interventional

The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty. In this view, we are collecting clinical data and biological samples of children attended as outpatients at the Pediatric Endocrine Center of Pisa from 1998 to present (the study is still open). From biological (blood) samples, gene polymorphisms such as endocrine disruptor levels are determined and compared to different growth pattern of pediatric patients treated with different GnRH agonists.